A Stock Tripled, Another Lost 58%: Tickeron AI Sorts Last Week's Mid-Cap Winners and Losers Under $100

Week of September 28 to October 2, 2026

Key Takeaways

• Biotech dominated both ends of the board. KOD nearly tripled (191.96%) on Phase 3 success, while LQDA collapsed 58.15% after losing a patent case to United Therapeutics.
• Chips and catalysts drove the gainers. $VSH, VECO and PDFS rallied with chip-equipment stocks, MAT jumped on reported takeover interest, and IOVA surged after raising its revenue outlook.
• Competition and financing fears drove the losers. DKNG hit a multiyear low as prediction markets gain ground, while VKTX and AXGN sank on financing and dilution worries.
• Tickeron AI's verdict is 11 BUYS and 9 SELLS. It sells winners trading above or near their analyst targets, and buys oversold losers where the targets still sit far above the price.
• Tickeron's AI Trading Bots rank each stock's sector strength, and its Financial Learning Models (FLM) read each stock's trend. Together they separate dips worth buying from falling knives.

The Market Backdrop

The week brought relief for growth stocks. September payrolls rose just 29,000 against 90,000 expected, and unemployment ticked up to 4.2%, which eased fears of more Fed hikes. Chip-equipment names stayed in favor after Micron's blowout results (Perplexity Finance). Speculative stocks with financing needs, however, kept getting sold.

How to read the tables: mid caps are US stocks worth $2B to $10B, and every stock here closed under $100. The weekly change runs from the September 25 close to the October 2 close, and YTD runs from the December 31, 2025 close. "Avg. target" is the average of the most recent analyst price targets, and "Upside" is the distance from the October 2 close to that average.

The 10 Biggest Winners

KOD (Kodiak Sciences) — BUY. 1-month forecast: UP. Kodiak's two eye drugs matched Eylea in Phase 3, and three firms raised their targets the same day, to an average of $120.33 that still implies +27.4% after the stock nearly tripled.

IOVA (Iovance Biotherapeutics) — BUY. 1-month forecast: UP. Iovance raised its revenue outlook and is guiding to 60% growth (Yahoo Finance), and HC Wainwright and Wells Fargo lifted their targets to an average of $19.00 (+33.6%).

LIND (Lindblad Expeditions) — SELL. 1-month forecast: DOWN. Up 141.2% YTD and at a new 52-week high (MarketBeat), the stock now trades above its $33.00 average analyst target (-5.1%), so lock in profits.

RXO (RXO) — SELL. 1-month forecast: DOWN. The freight-recovery pop pushed RXO above its $21.67 average target (-7.3%), and all three recent analysts rate it only Neutral or Equal-Weight.

VSH (Vishay Intertechnology) — SELL. 1-month forecast: DOWN. Vishay is up 163.5% YTD after a product launch and chip rally lifted shares (MarketBeat), but analysts are split (4 bullish, 4 hold, 2 bearish), and FLM reads the move as extended.

TTAN (ServiceTitan) — BUY. 1-month forecast: UP. Even after the weekly bounce, ServiceTitan is down 37.0% YTD with +42.1% to its $95.33 average target, and its Pantheon conference next week is a near-term catalyst (Investing.com).

VECO (Veeco Instruments) — SELL. 1-month forecast: DOWN. Up 100.8% YTD, Veeco has only +6.9% left to its $61.33 average target, so most of the chip-equipment rally is already priced in.

MAT (Mattel) — BUY. 1-month forecast: UP. Authentic Brands reportedly eyes a takeover of $6B or more (Yahoo Finance), well above Mattel's current $4.4B market value, making it a speculative deal play while the stock is still down 23.0% YTD.

PDFS (PDF Solutions) — BUY. 1-month forecast: UP. The chip-analytics software maker is riding rising earnings estimates, and DA Davidson's $74 target implies +33.3% upside.

S (SentinelOne) — SELL. 1-month forecast: DOWN. SentinelOne trades near its 52-week high of $25.75 with only +7.7% to its $27.00 average target, and Bernstein downgraded it to Market Perform in September.

The 10 Biggest Losers

LQDA (Liquidia) — SELL. 1-month forecast: DOWN. A Delaware court ruled that Yutrepia infringes United Therapeutics' patent (Yahoo Finance), and Wells Fargo downgraded the stock and slashed its target from $108 to $30, so wait for the appeal before stepping in.

NESR (National Energy Services Reunited) — BUY. 1-month forecast: UP. The oilfield-services firm is still up 57.5% YTD after a sharp four-week slide (Zacks), and UBS and Piper Sandler stay bullish with an average target of $42.50 (+72.3%).

WGS (GeneDx) — BUY. 1-month forecast: UP. The genetic-testing leader is down 43.8% YTD after a selloff tied to CMS fee schedules (Perplexity Finance), but Guggenheim raised its target to $83 this week and all three recent analysts are bullish (+19.9% to target).

VKTX (Viking Therapeutics) — BUY. 1-month forecast: UP. A financing overhang weighed on the obesity-drug developer (Quiver Quantitative), but its $88.67 average target implies +196.2%, the biggest discount on this list.

DKNG (DraftKings) — SELL. 1-month forecast: DOWN. DraftKings is down 46.1% YTD and hit a multiyear low as prediction-market rival Kalshi eyes a $40B valuation (Yahoo Finance), and BTIG just cut its target to $25.

GRND (Grindr) — SELL. 1-month forecast: DOWN. Grindr fell for two straight sessions even as the market was firm (Perplexity Finance), and its analyst targets date back to February through July, so FLM won't trust the +41.5% upside until the trend turns.

RIOT (Riot Platforms) — BUY. 1-month forecast: UP. Riot dropped 14.22% even as Bitcoin held steady near $84,400, and B. Riley raised its target to $33, giving an average target of $32.67 (+65.6%).

AXGN (AxoGen) — BUY. 1-month forecast: UP. The nerve-repair company's $208.7M stock offering (Investing.com) is now largely priced in, and both recent analysts hold $53 targets (+41.7%).

PPTA (Perpetua Resources) — BUY. 1-month forecast: UP. HC Wainwright reiterated its Buy and $43.50 target on September 30, and the average target of $36.75 implies +80.3% for this domestic antimony and gold developer.

ACHR (Archer Aviation) — SELL. 1-month forecast: DOWN. Archer is down 35.0% YTD and near its 52-week low of $4.30 amid eVTOL certification and funding worries, and its analyst targets are months old.

Scoreboard

How Tickeron's AI Trading Bots and FLM Made These Calls

Tickeron's AI Trading Bots start with the sector. They rank where money is flowing. This week that meant chip equipment, biotech with real data, and energy services. Money is flowing out of online betting and speculative eVTOL stocks. A winner in a strong sector with room to run gets a BUY; a winner that has already outrun its sector and its analyst targets gets a SELL.

Tickeron's Financial Learning Models (FLM) then read each stock's trend. FLM checks momentum, support levels and price patterns to judge whether a drop is a buyable dip or a broken chart. That's why $RIOT, AXGN and NESR get BUYS after their selloffs, while $DKNG, ACHR and LQDA get SELLS: their trends and catalysts still point lower.

Weekly winners and losers lists are where retail traders often get hurt, chasing the top or catching a falling knife. The bots tell you which sectors deserve your money, and FLM tells you when the trend agrees.

For informational purposes only; not investment advice. Prices as of the October 2, 2026 close. Tickeron AI forecasts are model-based estimates and do not guarantee future results.

Tickeron AI Perspective

 Disclaimers and Limitations